New combo tackles resistant myeloma in early trial
NCT ID NCT05391750
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests two drugs—venetoclax and tocilizumab—in people with a specific type of multiple myeloma (t(11;14)) that has come back or stopped responding to treatment. The study includes both African American and non-African American participants to see how safe the combination is and what dose works best. Only 7 people are enrolled, so the focus is on safety and side effects, not yet on curing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a drug that blocks Bcl-2 protein) and tocilizumab (a monoclonal antibody that blocks interleukin-6 receptor)
What this could lead to
If successful, this could point toward a new combination treatment for a specific type of multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early, small phase 1 trial with only 7 participants, so results may not apply broadly. The main goal is safety and dosing, not effectiveness, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States